Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In a phase 3 trial involving 103 pediatric patients with congenital adrenal hyperplasia, crinecerfont treatment resulted in a mean reduction of androstenedione levels by 197 ng/dL after 4 weeks, compared to an increase of 71 ng/dL in the placebo group.
Endocrinology, Diabetes, Metabolism August 21st 2024
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH